Information Provided By:
Fly News Breaks for July 23, 2019
KPTI
Jul 23, 2019 | 05:02 EDT
JPMorgan analyst Eric Joseph upgraded Karyopharm Therapeutics to Overweight from Neutral and doubled his price target for the shares to $16 from $8. The analyst says his doctor survey supports a "strong" Xpovio launch and long-term outlook.
News For KPTI From the Last 2 Days
There are no results for your query KPTI